Evofosfamide is under clinical development by Molecular Templates and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Evofosfamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Evofosfamide (TH-302) is under development for the treatment of metastatic pancreatic neuroendocrine tumors (pNET), hepatocellular carcinoma, human papillomavirus (HPV) negative squamous cell carcinoma of head and neck, recurrent glioblastoma (GBM) and metastatic biliary tract carcinoma including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma. The drug candidate is administered through intravenous route.
It was also under development for the treatment of metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma, metastatic soft tissue sarcoma, non-squamous non-small cell lung cancer, relapsed/refractory multiple myeloma, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, myelofibrosis, chronic lymphocytic leukemia (CLL), gastrointestinal stromal tumors, renal cell carcinoma (RCC), neuroblastoma, castration resistant prostate cancer, metastatic melanoma, esophageal cancer and adenocarcinoma of the gastroesophageal junction.
Molecular Templates overview
Molecular Templates (MTI), formerly Threshold Pharmaceuticals, is a clinical-stage oncology company. The company discovers and develops biologic therapeutics for cancer. It’s pipeline products include MT-5111, SLAMF-7, CTLA-4, MT-0169 and MT-6402. MTI lead product MT-3724, a fusion protein, is designed for the treatment of Non-Hodgkin Lymphoma; and MT-0169 is used for the treatment of multiple myeloma. The company also develops Engineered Toxin Bodies (ETBs) for the treatment of breast cancer, melanoma and allogeneic stem cell transplantation. It develops ETBs for various targets including CD20, CD38, HER2, and PD-L1. MTI is headquartered in Austin, Texas, the US.
For a complete picture of Evofosfamide’s drug-specific PTSR and LoA scores, buy the report here.